Marc Hirsch, MD, Eye Physician Associates, Milwaukee, WI My favorite medical journal is Ophthalmology, the journal sponsored by the American Academy of Ophthalmology. It’s got a lot of clinically relevant topics and it’s peer-reviewed, so I think it’s free of bias to some extent. Among peer-reviewed journals, this one has more clinically relevant research, where I’ve found…
GSW launches trends periodical
October 1, 2011
1:00 pm
inVentiv Health agency GSW Worldwide has launched a KOL Whitepaper called UP:ROOT, to be produced twice yearly. It will observe trends in healthcare and pharma marketing.
Ad sales rise at Medical Economics
October 1, 2011
1:00 pm
Medical Economics, a journal publication of Advanstar Communication’s medical division, has reported ad revenue growth of 49.6% in the first six months of 2011 over the first half of 2010.
Digital Media briefs
October 1, 2011
1:00 pm
Featuring news about Novo Nordisk, Quantia MD/Care Continuum Alliance and the Parkinson’s Disease Fondation
Pfizer’s Lipitor website touted the efficacy of Caduet, Chantix and Norvasc but the site failed to balance those claims by providing any risk information for the drugs, according to an “untitled letter” from the FDA’s Division of Drug Marketing, Advertising and Communication (DDMAC).
LEO Pharma, Inc., a wholly owned US subsidiary of the 100-year old Danish organization LEO Pharma A/S, has reported growth of 85% in the overall sales force associated with the company since it officially launched in January 2010.
Oral anticoagulant Eliquis (apixaban) has demonstrated superior efficacy and bleeding profile to standard warfarin therapy. Barring any bombshells, that should be enough for this agent, being developed by Pfizer and Bristol-Myers Squibb, to get US approval and form a compelling sales narrative in the warfarin-alternative market, analysts say.